FDA Alert: Unique Pharmaceutical Recalls Cetirizine Tablets Over Ranitidine Cross-Contamination

3 min read|690 words

✓ Editorially Reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD — GMJ News Desk

🟡 Regulatory Alert

Unique Pharmaceutical Laboratories, a division of J. B. Chemicals & Pharmaceuticals Ltd. (based in Panoli, Gujarat), has initiated a voluntary nationwide recall of four lots of Cetirizine Hydrochloride Tablets USP 5 mg due to potential cross-contamination with ranitidine, according to a U.S. Food and Drug Administration (FDA) alert issued July 18, 2026. The recall extends to the consumer level and affects patients who may be taking the antihistamine medication.

Key takeaways

Four specific lots of 5 mg cetirizine tablets are being recalled due to ranitidine cross-contamination
The recall is voluntary and extends to the consumer level, requiring patient awareness and action
Ranitidine was previously removed from the market in 2020 due to impurity concerns; any cross-contamination poses a potential safety risk
Patients should contact their healthcare provider or pharmacist to confirm whether their medication is affected

Background: The ranitidine safety precedent

Ranitidine, a histamine-2 receptor antagonist used to reduce stomach acid, was voluntarily withdrawn from the global market in 2020 after the FDA and other regulatory agencies found that the drug could degrade into N-nitrosodimethylamine (NDMA), a probable human carcinogen. This contamination issue prompted the FDA to request the withdrawal of all ranitidine-containing products from manufacturers worldwide. The presence of ranitidine—even in trace amounts through cross-contamination—in a cetirizine product therefore presents a potential health risk to consumers, particularly with regard to carcinogenic impurities.

Scope and action required

The recall involves cetirizine hydrochloride tablets manufactured by Unique Pharmaceutical Laboratories and affects specific lot numbers that may contain ranitidine residues. According to the FDA’s safety alert, patients currently taking the affected cetirizine tablets should consult their healthcare provider, pharmacist, or poison control centre immediately if they have questions or experience adverse effects. Healthcare professionals are being advised to verify lot numbers against the FDA’s recall database and counsel patients to discontinue use of recalled products.

Submit Your Paper

Ranitidine market withdrawal timeline

Key regulatory milestones in the ranitidine contamination crisis, 2019–2026

2019

FDA receives initial NDMA contamination reports

2020

Ranitidine voluntarily withdrawn globally

2026

Cross-contamination detected in cetirizine supply

Source: FDA Safety Alerts, 2019–2026 | Georgian Medical Journal News

Manufacturing oversight and preventive measures

The discovery of ranitidine in cetirizine tablets highlights the importance of robust pharmaceutical manufacturing controls and segregation protocols. According to the FDA’s broader recall framework, manufacturers are required to maintain strict quality assurance procedures to prevent cross-contamination between active pharmaceutical ingredients, particularly when handling substances that have been removed from the market due to safety concerns. Unique Pharmaceutical Laboratories’ voluntary recall demonstrates the importance of post-manufacturing testing and traceability systems in the pharmaceutical supply chain.

Four lots of Cetirizine Hydrochloride Tablets USP 5 mg have been recalled due to potential cross-contamination with ranitidine, a substance removed from the market in 2020 due to carcinogenic impurity (NDMA) risks.

— U.S. Food and Drug Administration (FDA), July 18, 2026

What this means

For patients: If you are currently taking cetirizine 5 mg tablets, check the lot number on your medication bottle against the FDA recall list. If your lot is affected, stop use immediately and consult your pharmacist or doctor for an alternative antihistamine. Do not dispose of recalled medication down the drain or in household waste—contact your local pharmacy for safe disposal guidance.

For clinicians: When prescribing or dispensing cetirizine, verify that the product is not from a recalled lot. Counsel patients on the recall status and ensure continuity of allergy management by offering alternative first-generation or second-generation antihistamines (e.g., fexofenadine, loratadine) if cetirizine is unavailable. Document the recall discussion in the patient’s medical record.

For policymakers: This incident reinforces the need for strengthened pharmaceutical manufacturing inspections, particularly at facilities with international supply chains. Regulatory agencies should enhance post-market surveillance capabilities and accelerate adoption of blockchain-based supply chain tracking to detect contamination events earlier and reduce the scope of recalls.

Read more about pharmacy and prescribing alerts and quality and safety standards in healthcare.

The recall underscores the enduring regulatory challenge posed by ranitidine’s legacy contamination and the continued vigilance required to protect patients across global pharmaceutical supply chains. Healthcare systems and individual consumers should remain alert to FDA safety communications and participate actively in medication verification and reporting to ensure product safety.

Source: FDA Safety Alert: Unique Pharmaceutical Laboratories Cetirizine Recall, July 18, 2026

Was this article helpful?